About Modis Therapeutics
Focused on disease-modifying therapies
Modis Therapeutics is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need. We were formed in 2016 through a collaboration with academic experts in mitochondrial biology. Our lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease.
About TK2 Deficiency
A progressive, devastating mitochondrial disease
Thymidine kinase 2 deficiency is a genetic disorder that results in mitochondrial dysfunction, leading to inadequate energy production in cells. TK2d causes progressive and severe muscle weakness, respiratory insufficiency, loss of motor function, and is often fatal. There are currently no approved therapies for this disease.
MT1621 for TK2d
Deoxynucleoside combination therapy to restore mitochondrial function
Our science is based on discoveries by our academic collaborators that deoxynucleoside combination therapy can restore cellular function in a subset of mitochondrial diseases – mitochondrial DNA (mtDNA) depletion disorders. Data from initial clinical studies suggest that this novel approach may reverse or slow disease progression in TK2 deficient patients.
Preclinical proof-of-concept established
Initial clinical data suggest meaningful treatment benefit
Accelerated development pathway
News
February 19, 2019
Modis Therapeutics Announces that MT1621 Receives Breakthrough Therapy Designation from FDA for the Treatment of TK2 Deficiency
November 13, 2018
Modis Therapeutics Announces PRIME Designation Granted by the European Medicines Agency to MT1621 for the Treatment of TK2 Deficiency
October 29, 2018
Modis Therapeutics Announces Appointment of Matthew R. Patterson to Board of Directors
